Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report.
Adolescent
Blood Chemical Analysis
COVID-19
COVID-19 Testing
Ceftriaxone
/ administration & dosage
China
Clinical Laboratory Techniques
/ methods
Coronavirus Infections
/ diagnosis
DNA, Viral
/ analysis
Diagnosis, Differential
Disease Progression
Drug Therapy, Combination
Electrocardiography
/ methods
Follow-Up Studies
Hospitalization
Humans
Hydroxychloroquine
/ administration & dosage
Macrophage Activation Syndrome
/ diagnosis
Male
Pandemics
Patient Discharge
Pneumonia, Viral
/ diagnosis
Radiography, Thoracic
/ methods
Real-Time Polymerase Chain Reaction
/ methods
Risk Assessment
Severity of Illness Index
Tomography, X-Ray Computed
/ methods
Treatment Outcome
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
07 Aug 2020
07 Aug 2020
Historique:
entrez:
10
8
2020
pubmed:
10
8
2020
medline:
15
8
2020
Statut:
ppublish
Résumé
Macrophage activation syndrome (MAS) is a rare life-threatening condition characterized by cytokine-mediated tissue injury and multiorgan dysfunction. We describe the unique case of young man who developed MAS as the sole manifestation of an otherwise paucisymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clinical and biological criteria led to the diagnosis of MAS; cytokine profile was highly suggestive reverse transcription polymerase chain reaction for SARS-CoV-2 in nasopharyngeal swabs was negative, but serum anti-SARS-CoV-2 immunoglobulin A and immunoglobulin G resulted positive leading to the diagnosis of SARS-CoV-2 infection. The patient was treated with empiric antibiotic and hydroxychloroquine. Clinical improvement ensued. At follow-up, the patient is well. SARS-CoV-2 infection may trigger develop life-threatening complications, like MAS. This can be independent from coronavirus disease 2019 gravity.
Identifiants
pubmed: 32769902
doi: 10.1097/MD.0000000000021570
pii: 00005792-202008070-00043
pmc: PMC7593078
doi:
Substances chimiques
DNA, Viral
0
Hydroxychloroquine
4QWG6N8QKH
Ceftriaxone
75J73V1629
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21570Références
Lupus. 2018 Jun;27(7):1065-1071
pubmed: 29451069
Best Pract Res Clin Rheumatol. 2020 Aug;34(4):101515
pubmed: 32387063
Front Med (Lausanne). 2020 Apr 24;7:184
pubmed: 32391371
Lancet. 2020 May 22;:
pubmed: 32450107
Best Pract Res Clin Rheumatol. 2014 Apr;28(2):277-92
pubmed: 24974063
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265